[{"id":"dc334b0f-8b5c-4b2f-8468-f243cf63a6a0","acronym":"NCI-2022-09458","url":"https://clinicaltrials.gov/study/NCT05627635","created_at":"2022-11-25T15:58:22.182Z","updated_at":"2025-02-25T15:20:07.740Z","phase":"Phase 1/2","brief_title":"FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05627635 - NCI-2022-09458","lead_sponsor":"City of Hope Medical Center","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2025","study_completion_date":" 10/07/2025","last_update_posted":"2025-02-12"},{"id":"d6a707a3-bb85-4ce5-8066-8bc03501bcf5","acronym":"C-800-01","url":"https://clinicaltrials.gov/study/NCT03860272","created_at":"2023-03-25T19:00:32.588Z","updated_at":"2025-02-25T16:37:22.836Z","phase":"Phase 1","brief_title":"Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer","source_id_and_acronym":"NCT03860272 - C-800-01","lead_sponsor":"Agenus Inc.","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 499","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 01/13/2025","primary_completion_date":" 01/13/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-06"},{"id":"80af2132-83d6-4705-a7c2-701bcc6ce4a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06336902","created_at":"2024-03-29T16:39:58.679Z","updated_at":"2025-02-25T17:03:18.664Z","phase":"Phase 1","brief_title":"Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients with KRAS-Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06336902","lead_sponsor":"University of Southern California","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/15/2025","start_date":" 01/15/2025","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2028","study_completion_date":" 01/15/2028","last_update_posted":"2025-02-03"},{"id":"b7163c5c-0370-418e-8711-fbb409699d7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02962063","created_at":"2021-01-18T14:33:31.039Z","updated_at":"2025-02-25T15:07:20.200Z","phase":"Phase 1/2","brief_title":"Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer","source_id_and_acronym":"NCT02962063","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-10-16"},{"id":"4097b476-e251-40e9-8dd4-e80b740ce49e","acronym":"NCI-2018-01189","url":"https://clinicaltrials.gov/study/NCT03132467","created_at":"2021-01-18T15:26:00.796Z","updated_at":"2024-07-02T16:34:38.153Z","phase":"Phase 1","brief_title":"Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer","source_id_and_acronym":"NCT03132467 - NCI-2018-01189","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 amplification • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 01/31/2019","primary_completion_date":" 01/31/2019","study_txt":" Completion: 05/20/2024","study_completion_date":" 05/20/2024","last_update_posted":"2024-06-05"},{"id":"6a7437dd-1b7b-49b8-8341-ff9ad04a3230","acronym":"C-800-25","url":"https://clinicaltrials.gov/study/NCT05608044","created_at":"2022-11-08T15:56:56.796Z","updated_at":"2024-07-02T16:34:59.296Z","phase":"Phase 2","brief_title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","source_id_and_acronym":"NCT05608044 - C-800-25","lead_sponsor":"Agenus Inc.","biomarkers":" EGFR • BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["EGFR • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-06-04"},{"id":"17124774-125f-48f3-9fa4-bdffab757f3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06300463","created_at":"2024-03-12T14:20:52.081Z","updated_at":"2024-07-02T16:35:09.965Z","phase":"Phase 2","brief_title":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","source_id_and_acronym":"NCT06300463","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-12"},{"id":"6003592e-c212-4e12-bf84-ded1b1c44edb","acronym":"CIME","url":"https://clinicaltrials.gov/study/NCT06346197","created_at":"2024-04-03T23:39:52.167Z","updated_at":"2024-07-02T16:35:11.577Z","phase":"Phase 3","brief_title":"Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas","source_id_and_acronym":"NCT06346197 - CIME","lead_sponsor":"Centre Leon Berard","biomarkers":" TMB • LAG3 • TIGIT","pipe":"","alterations":" ","tags":["TMB • LAG3 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 05/15/2028","primary_completion_date":" 05/15/2028","study_txt":" Completion: 05/15/2028","study_completion_date":" 05/15/2028","last_update_posted":"2024-04-03"},{"id":"0fa8ab04-e7a7-4cdf-a8ec-f0b54cef76dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04121676","created_at":"2022-01-21T18:55:54.943Z","updated_at":"2024-07-02T16:35:12.106Z","phase":"Phase 1","brief_title":"Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer","source_id_and_acronym":"NCT04121676","lead_sponsor":"Agenus Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e botensilimab (AGEN1181) • AGEN2373"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-04-01"},{"id":"68f2972e-8669-4ad3-868c-69f2477d1d11","acronym":"OMNIA-1","url":"https://clinicaltrials.gov/study/NCT05578872","created_at":"2022-10-13T17:58:21.130Z","updated_at":"2024-07-02T16:35:19.846Z","phase":"Phase 1/2","brief_title":"A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).","source_id_and_acronym":"NCT05578872 - OMNIA-1","lead_sponsor":"Anaveon AG","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600 • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • ANV419"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 12/16/2022","start_date":" 12/16/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-12"},{"id":"59c4433e-178c-41e8-bb65-1d9a0a1d95a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631899","created_at":"2022-11-30T17:57:34.718Z","updated_at":"2024-07-02T16:35:20.773Z","phase":"Phase 1","brief_title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05631899","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-02-06"},{"id":"06240d3a-65df-4d82-9307-690aa6491b9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529316","created_at":"2022-09-07T16:55:49.888Z","updated_at":"2024-07-02T16:35:23.516Z","phase":"Phase 2","brief_title":"A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma","source_id_and_acronym":"NCT05529316","lead_sponsor":"Agenus Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Suspended","enrollment":" Enrollment 220","initiation":"Initiation: 12/12/2022","start_date":" 12/12/2022","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-01-12"},{"id":"307f58ff-e40c-4fdc-bf96-004db83003a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06076837","created_at":"2023-10-11T16:12:25.578Z","updated_at":"2024-07-02T16:35:33.893Z","phase":"Phase 1","brief_title":"The Seven Trial: Exploiting the Unfolded Protein Response","source_id_and_acronym":"NCT06076837","lead_sponsor":"HonorHealth Research Institute","biomarkers":" CEACAM5 • MUC16","pipe":"","alterations":" ","tags":["CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • albumin-bound paclitaxel • balstilimab (AGEN2034) • botensilimab (AGEN1181) • celecoxib oral • chloroquine phosphate"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-11"},{"id":"b1f6561e-f7b3-4a30-aa92-3da38e910039","acronym":"","url":"https://clinicaltrials.gov/study/NCT04043195","created_at":"2021-01-18T19:49:58.881Z","updated_at":"2024-07-02T16:35:40.376Z","phase":"Phase 1/2","brief_title":"Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC","source_id_and_acronym":"NCT04043195","lead_sponsor":"Hatim Husain","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/14/2019","start_date":" 08/14/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-10"},{"id":"119219a5-41c8-4ccd-b3d3-65d472efd573","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672316","created_at":"2023-01-05T14:58:30.826Z","updated_at":"2024-07-02T16:35:41.799Z","phase":"Phase 1/2","brief_title":"Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy","source_id_and_acronym":"NCT05672316","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 11/09/2024","primary_completion_date":" 11/09/2024","study_txt":" Completion: 11/09/2024","study_completion_date":" 11/09/2024","last_update_posted":"2023-07-27"},{"id":"e9e3aecb-fa86-45d0-aff4-2b14460653e5","acronym":"CSWOG-C03","url":"https://clinicaltrials.gov/study/NCT05426005","created_at":"2022-06-21T23:54:40.688Z","updated_at":"2024-07-02T16:35:55.939Z","phase":"Phase 1/2","brief_title":"Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer","source_id_and_acronym":"NCT05426005 - CSWOG-C03","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/07/2023","start_date":" 02/07/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-02-09"},{"id":"6b8da668-3452-4f5c-9ff3-8baba01ae0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634058","created_at":"2021-01-19T20:37:05.920Z","updated_at":"2024-07-02T16:35:56.030Z","phase":"Phase 2","brief_title":"PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment","source_id_and_acronym":"NCT04634058","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" CTLA4","pipe":"","alterations":" ","tags":["CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiLi (adebrelimab) • Tabosun (ipilimumab N01 injection)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-02-08"},{"id":"996d882f-fae7-40b0-9fb5-12daec76b9ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04607200","created_at":"2021-01-19T20:31:41.807Z","updated_at":"2024-07-02T16:36:18.687Z","phase":"Phase 2","brief_title":"AGEN2034 \u0026 AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma","source_id_and_acronym":"NCT04607200","lead_sponsor":"Agenus Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • zalifrelimab (UGN-301)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 09/13/2021","primary_completion_date":" 09/13/2021","study_txt":" Completion: 09/13/2021","study_completion_date":" 09/13/2021","last_update_posted":"2022-01-11"}]